Exegenesis Bio specializes in gene therapy for genetic disorders by employing viral vectors for targeted gene delivery to correct specific genetic mutations. The company aims to enhance patient outcomes by providing precise therapeutic interventions that address the root causes of these conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Many genetic disorders lack effective treatments that address the underlying genetic mutations, leading to progressive disease and limited therapeutic options. Traditional approaches often fail to provide targeted and sustained correction of these genetic defects.
Solution
Exegenesis Bio is a clinical-stage gene therapy company developing innovative genetic medicines for a range of diseases. The company leverages proprietary AAV (adeno-associated virus) capsid technology, AI-aided DNA expression cassette design, and data-driven protein engineering to create targeted gene therapies. These therapies aim to deliver functional genes to specific cells, correcting the genetic mutations at the root of the disease. Exegenesis Bio's pipeline focuses on developing one-time curative treatments for diseases affecting the central nervous system (CNS), liver, and eyes, with the goal of improving efficacy, safety, and patient access.
Target Audience
The primary target audience includes patients with genetic disorders, their families, and healthcare providers seeking advanced therapeutic options, as well as pharmaceutical companies looking for strategic partnerships in gene therapy development.
Features
- AAVarta®: An in-silico AAV capsid evolution discovery platform for improved tissue targeting
- Constellation®: An AI-aided DNA expression cassette design platform for optimized gene expression
- Progress®: A data-driven protein engineering platform for enhanced protein function
- Development of novel capsids for targeted delivery to the heart and liver
- cGMP manufacturing facilities with 500L and 2,000L disposable bioreactors for viral vectors
- EXG102: rAAV-based gene therapeutic vector expressing a fusion protein that binds VEGF (A/B/C) and Angiopoietin 2, delivered via Subretinal Injection
- EXG202: Next generation gene therapy that uses the same payload as EXG102, but is packaged in a proprietary, engineered AAV capsid that targets retinal tissues more specifically and more efficiently, enabling delivery via Intravitreal Injection